LARGON
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1960
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LARGON is an injectable medication approved in 1960 with an unknown mechanism of action and indication profile. The generic name and pharmacologic class remain unspecified in available data. Patient population and therapeutic use cannot be characterized without indication data.
LOE Approaching
Product is approaching loss of exclusivity with 30% competitive pressure; teams are likely focused on lifecycle management and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate limited hiring momentum on LARGON; roles on this product focus on managing mature asset through LOE transition. Career growth opportunities are constrained compared to launch-stage or peak-stage products.
Brand ManagerField Sales Representative
Worked on LARGON at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.